GSK 3390107A

Drug Profile

GSK 3390107A

Alternative Names: cAd3 EBO Z; ChAd3 Ebola candidate vaccine - GSK; ChAd3-EBO-Z; Chimp Adenovirus type 3 Ebola vaccine - GSK; GSK 3390107 A; Monovalent Ebola vaccine - NIAID/Okairos; Monovalent Ebola vaccine - Okairos/NIAID; Monovalent Ebola virus vaccine - NIAID/Okairos; Monovalent Ebola virus vaccine - Okairos/NIAID; Monovalent Zaire Ebola Chimpanzee Adenovirus vector vaccine; VRC-EBOADC076-00-VP

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; Okairos
  • Developer National Institute of Allergy and Infectious Diseases; ReiThera; The Jenner Institute; University Hospital of Lausanne; University of Oxford
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ebola virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention, In volunteers) in United Kingdom (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention, In volunteers, In adults) in USA (IM, Injection)
  • 15 May 2017 GlaxoSmithKline completes a phase II clinical trial for Ebola virus infections (In adolescents, In children, In infants, Prevention) in Mali and Senegal (IM) (NCT02548078)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top